CRL News and Press, Charles River Laboratories International Inc.

2024-07-19 02:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Renewed leadership by ...

2024-07-18 07:40:00 ET Summary SMID caps gave back some of their first quarter gains with the Russell 2500 index delivering a total return of -4.27%. For the second quarter of 2024, the Aristotle Small/Mid Cap Equity Composite generated a total return of -1.83 % net of fees (-1.69...

Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...

2024-07-16 12:15:00 ET Summary The Sustainable Value Strategy outperformed its benchmark for the quarter and year-to-date period. Pockets of opportunity exist for small caps supplying AI hyperscalers in chip development and data center construction. We believe there is tremend...

Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good...

2024-07-06 07:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. During the quarter, a ...

2024-06-28 13:20:06 ET More on Charles River Laboratories Charles River Laboratories: Fair Valuation Against Fundamentals Charles River Laboratories International, Inc. (CRL) Q1 2024 Earnings Call Transcript Mizuho starts Charles River Labs at neutral, cites near-ter...

Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract...

2024-06-18 18:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Leveraging CGT CDMO expertise to support T-cell immunotherapy clinical trial Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector productio...